Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 253-446-5 | CAS number: 37288-54-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The repeated dose oral toxicity of Mannanase has been tested by oral gavage in Han Wistar rats. Dosing of the animals at doses up to 100% of the Mannanase, batch PPE42634 (equivalent to 1277 mg enzyme concentrate dry matter/kg bw/day) for 13 weeks was well-tolerated and there was no significant finding of any toxicological relevance. The no-observed-adverse-effect level (NOAEL) in this study was considered to be 100% Mannanase, batch PPE42634 equivalent to 1277 mg enzyme concentrate dry matter/kg bw/day.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 20 December 2016 to 13 September 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- This assessment of sub-chronic systemic toxicity (according to OECD TG 408) has been performed due to data requirements from the European Food Safety Authority (EFSA), as this enzyme also comply with the regulatory system of FIAP [REGULATION (EC) No 1331/2008 and EFSA CEF guidance from 2009/2013]. Moreover; it has been generated in accordance with Directive 2010/63/EU.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- 1998
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on species / strain selection:
- RccHanTM:WIST rat.
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Envigo RMS Limited
- Females nulliparous and non-pregnant: Yes
- Age at study initiation: 41-47 days
- Weight at study initiation: 160 to 200 g for males; 122-161 g for females
- Fasting period before study: None
- Housing: 5 animals of the same sex per cage
- Diet: Teklad 2014C Diet ad libitum (removed overnight before blood sampling for hematology or blood chemistry).
- Water: Ad libitum. Potable water from the public supply via polycarbonate bottles with sipper tubes.
- Acclimation period: 15 days
ENVIRONMENTAL CONDITIONS
- Temperature : 20-24°C
- Humidity : 40-70 % RH
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 21 December 2016 To: 26 May 2017 - Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- reverse osmosis water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test enzyme was provided deep-frozen in a number of containers, which were further divided (for highest group formulations) or used for dilution procedures to provide sufficient aliquots for each day of the study. Bulk containers were defrosted in a
refrigerator overnight prior to preparation of the daily aliquots for study use. The final study aliquots and any remaining test-item were returned to the freezer as soon as practical. Bulk containers were stirred using a magnetic stirrer gently to ensure homogeneity prior to preparation of the daily aliquots. Daily aliquots were prepared on a weekly basis. Daily aliquots were either stored at ambient temperature (in cases where the formulations were prepared and administered on the same day) or were stored frozen (-10 to -30°C) and either thawed overnight in a refrigerator (2 to 8°C), if dose administration was conducted on the following day, or thawed at ambient temperature if dose administration was conducted on the same day. In either case, formulations were allowed to equilibrate at room temperature before dosing and were administered within 24 hours of the commencement of thawing procedures.
- Concentration in vehicle: 10, 33 and 100%, corresponding to 128, 425 and 1277 mg enzyme concentrate dry matter/kg bw/day.
- Amount of vehicle (if gavage): constant volume 10 mL/kg body weight.
- Purity: Reverse osmosis water - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Dose samples were analysed according to GLP.
Stability of 10 and 100% formulations when retained for up to 24 hours refrigerated (2 to 8°C) or at ambient temperature (15 to 25°C), and up to 168 hours (seven days) when stored deep-frozen (-10 to -30°C) were demonstrated by Novozymes A/S. Samples of each formulation prepared for administration in Weeks 1, 6 and 13 of treatment were analyzed for total nitrogen content (%). - Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- Daily
- Dose / conc.:
- 128 mg/kg bw/day (nominal)
- Remarks:
- mg enzyme concentrate dry matter/kg bw/day
- Dose / conc.:
- 425 mg/kg bw/day (nominal)
- Remarks:
- mg enzyme concentrate dry matter/kg bw/day
- Dose / conc.:
- 1 277 mg/kg bw/day (nominal)
- Remarks:
- mg enzyme concentrate dry matter/kg bw/day
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The test enzyme was not anticipated to cause any significant findings, based on the results obtained from studies with similar materials. The highest dose (100%) is the maximum practical dose and represents administration of the enzyme, as received, at a volume dosage of 10 mL/kg body weight. The lower doses were selected using a ratio of approximately 3.3 between doses.
- Positive control:
- N/A
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: At least once daily
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Animals were inspected visually at least twice daily for evidence of ill-health or reaction to treatment.
BODY WEIGHT: Yes
- Time schedule for examinations: The weight of each animal was recorded one week before treatment commenced, on the day that treatment commenced (Day 1), weekly throughout the study and before necropsy.
FOOD CONSUMPTION:
- The weight of food supplied to each cage, that remaining and an estimate of any spilled was recorded for the week before treatment started and for each week throughout the study.
WATER CONSUMPTION:
- Time schedule for examinations: Daily by visual observation.
OPHTHALMOSCOPIC EXAMINATION: Yes
- Time schedule for examinations: All aniumals before treatment started and during week 13 (animals from Groups 1 and 4).
- Dose groups that were examined: All animals before treatment. Control and highest dose group after treatment.
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Week 13
- Anaesthetic used for blood collection: Yes (isoflurane anaesthesia)
- Animals fasted: Yes, overnight
- How many animals: From all animals
- Parameters checked:
Haematocrit (Hct)
Hemoglobin (Hb)
Erythrocyte count (RBC)
Absolute reticulocyte count (Retic)
Mean cell hemoglobin (MCH)
Mean cell hemoglobin concentration (MCHC)
Mean cell volume (MCV)
Red cell distribution width (RDW)
Total white cell count (WBC)
Platelet count (Plt)
Differential WBC count:
Neutrophils (N)
Lymphocytes (L)
Eosinophils (E)
Basophils (B)
Monocytes (M)
Large unstained cells (LUC)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Week 13
- Animals fasted: Yes, overnight
- How many animals: From all animals
- Parameters checked:
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Urea
Creatinine (Creat)
Glucose (Gluc)
Total cholesterol (Chol)
Sodium (Na)
Potassium (K)
Total protein (Total Prot)
Albumin (Alb)
Albumin/globulin ratio (A/G Ratio)
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: yes
- Time schedule for examinations: During week 12
- Dose groups that were examined: all
- Battery of functions tested: sensory activity / grip strength / motor activity / : Yes - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Other examinations:
- FAECAL ANALYSIS: No
Hematology, Bone Marrow: Yes
Weight of individual organs: Yes
- Time schedule for collection of organs: At necropsy - Statistics:
- The main tests used were Dunnett’s test, Shirley’s test, Williams’ test, Steel's test, Fisher's exact test and Barlett's test. Significant differences between the groups compared were expressed at the 5% (p<0.05) or 1% (p<0.01) level.
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- All differences from controls, including those that attained statistical significance, were minor, confined to one sex, lacked dose-relationship and were within the background range and, consequently, were attributed to normal biological variation.
In males there was a single high dose male with a total leucocyte count that was slightly below the concurrent control values and just below the background range.
The statistically significantly reduced prothrombin times in females receiving 33% Mannanase was clearly incidental in the absence of a similar finding at the highest doseand with the majority (9/10) of values within the background range. - Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- The biochemical analysis of the plasma in Week 13 did not identify any difference from controls that was attributable to treatment. All differences from controls, including those that attained statistical significance, were minor, confined to one sex, lacked dose-relationship and were within the background range and, consequently, were attributed to normal biological variation.
At all doses there was a statistically significantly high plasma creatinine concentration in males but this was attributed to five control animals having values that were below the background range leading to a lower than expected group mean value for the control males. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Neuropathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 277 mg/kg bw/day (nominal)
- Based on:
- other: mg enzyme concentrate dry matter
- Sex:
- male/female
- Basis for effect level:
- other: there are no adverse effects observed at the highest dose tested
- Key result
- Critical effects observed:
- no
- Conclusions:
- It is concluded that oral administration of Mannanase, batch PPE42634 to Han Wistar rats at doses up to 100% of the Mannanase, batch PPE42634 (equivalent to 1277 mg enzyme concentrate dry matter/kg bw/day) for 13 weeks was well-tolerated and there was no significant finding of any toxicological relevance. The no-observed-adverse-effect level (NOAEL) in this study was considered to be 100% Mannanase, batch PPE42634 equivalent to 1277 mg enzyme concentrate dry matter/kg bw/day.
- Executive summary:
The purpose of this study was to assess the systemic toxic potential of Mannanase, batch PPE42634 (an enzyme used in the food industry), when administered orally by gavage to Han Wistar rats for 13 weeks. Three groups, each comprising ten males and ten females, received doses of 10, 33 or 100% of Mannanase, batch PPE42634 (equivalent to 128, 425 and 1277 mg enzyme concentrate dry matter/kg body weight/day). A similarly constituted control group received the vehicle (reverse osmosis water) at the same volume-dose (10 mL/kg body weight) as the treated groups. During the study, clinical condition, detailed physical and arena observations, sensory reactivity, grip strength, motor activity, body weight, food consumption, visual water consumption, ophthalmic examination, hematology (peripheral blood), blood chemistry, organ weight, macropathology and histopathology investigations were undertaken.
There was no death and no clinical sign, behavioral finding that were attributable to treatment. In addition there was no effect of treatment on bodyweight or food and water consumption. There was no treatment-related ophthalmoscopic finding. The haematological analysis of the peripheral blood and biochemical analysis of the plasma in Week 13 did not identify any difference from controls that was attributable to treatment. Organ weights were unaffected after 13 weeks and there was no treatment related.
It is concluded that oral administration of Mannanase, batch PPE42634 to Han Wistar rats at doses up to 100% of the Mannanase, batch PPE42634 (equivalent to 1277 mg enzyme concentrate dry matter/kg bw/day) for 13 weeks was well-tolerated and there was no significant finding of any toxicological relevance. The no-observed-adverse-effect level (NOAEL) in this study was considered to be 100% Mannanase, batch PPE42634 equivalent to 1277 mg enzyme concentrate dry matter/kg bw/day.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 277 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
- Quality of whole database:
- Toxicological data has been generated within the enzyme producing industry during the last 40 years. Substantial documentation on the safety of the production strains have been generated, and the enzyme test materials are thoroughly characterized. High quality studies for all relevant endpoints, in vivo studies as well as in vitro studies, show that industrial enzymes from well-known and well-characterized production strains have very similar safety profiles across the catalytic activities. Read-across can therefore be applied for the majority of toxicological endpoints. The database can thus be considered of high quality.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Quality of whole database:
- Toxicological data has been generated within the enzyme producing industry during the last 40 years. Substantial documentation on the safety of the production strains have been generated, and the enzyme test materials are thoroughly characterized. High quality studies for all relevant endpoints, in vivo studies as well as in vitro studies, show that industrial enzymes from well-known and well-characterized production strains have very similar safety profiles across the catalytic activities. Read-across can therefore be applied for the majority of toxicological endpoints. The database can thus be considered of high quality.
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
A repeated dose oral toxicity study was conducted according to OECD guideline 408 (adopted 1998) and in compliance with GLP. The conclusion was that the No Observed Adverse Effect Level (NOAEL) in rats was the highest dose level tested, equivalent to 10 mL of undiluted test material/kg bw/day or 1277 mg enzyme concentrate dry matter/kg bw/day.
The repeated dose inhalation and dermal toxicity studies were waived.
- The dermal study was waived because of the low likelihood of absorption of enzymes through the skin due to the physico-chemical properties and the large size of the enzyme protein.
- The inhalation study was waived because exposure is too low to exert any toxicity. Potential exposure by inhalation to an amount of enzyme that toxicologically relevant is unrealistic, due to the formulation of enzymes and the stringent work practices, enforced because of the risk of sensitisation by inhalation. In addtion, the acute inhalation exposure of up to 450 mg enzyme concentrate dry matter/m3 did not show any adverse effects.
Justification for classification or non-classification
Based on repeated dose oral study and weight of evidence, mannanase does not exert any repeated dose oral, dermal or inhalation toxicity to workers or consumers.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.